DURECT CORP
DRRX evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Lead Asset:
- larsucosterol (Phase 2)
What it means
What to watch
Prepared research question
What matters most for DRRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 2 pipeline candidates for DURECT CORP.
Similar companies
Run DURECT CORP through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available DURECT CORP facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is DURECT CORP's lead drug candidate?
DURECT CORP's most advanced tracked candidate is larsucosterol (Phase 2) for Alcohol-associated hepatitis (AH).
Who is the CEO of DURECT CORP?
James E. Brown is the chief executive officer of DURECT CORP (DRRX).
What therapeutic areas does DURECT CORP focus on?
DURECT CORP develops therapies across Infectious Disease, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.